The inhibition of COX-2 was also shown to negatively impact immune evasion of tumor cells, as its inhibition was shown to synergize with PD-L1 blockade suggesting that COX inhibitors could be used in combination with immunotherapy (170). This evidence concerns the gene PTGS2 and neoplasm.